ArticleNanomedicine : nanotechnology, biology, and medicine2014
Molecular characterization of scant lung tumor cells using iron-oxide nanoparticles and micro-nuclear magnetic resonance.
Article in Nanomedicine : nanotechnology, biology, and medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 39 citations in OpenAlex.
- Magnetic nanoparticles for cancer theranostics.Biomedical physics & engineering express · 2026Review
- COACS omega · 2025Article
- Development and validation of a controlled heating apparatus for long-term MRI of 3D microfluidic tumor models.AIChE journal. American Institute of Chemical Engineers · 2024Article
- Isolation, Detection and Analysis of Circulating Tumour Cells: A Nanotechnological Bioscope.Pharmaceutics · 2023Review
- Crystal Plane Impact of ZnFeACS omega · 2022Article
- Liquid Biopsy-Based Biosensors for MRD Detection and Treatment Monitoring in Non-Small Cell Lung Cancer (NSCLC).Biosensors · 2021Review
- Recent Advances in Aptamer-Based Biosensors for Detection ofFrontiers in microbiology · 2020Review
- National Cancer Institute Alliance for nanotechnology in cancer-Catalyzing research and translation toward novel cancer diagnostics and therapeutics.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2019Review
- Review
- Article
- SPIO-loaded nanostructured lipid carriers as liver-targeted molecular T2-weighted MRI contrast agent.Quantitative imaging in medicine and surgery · 2018Article
- Advances in liquid biopsy on-chip for cancer management: Technologies, biomarkers, and clinical analysis.Critical reviews in clinical laboratory sciences · 2018Review
- Biosensing Using Magnetic Particle Detection Techniques.Sensors (Basel, Switzerland) · 2017Review
- Article
- Advancing biomedical imaging.Proceedings of the National Academy of Sciences of the United States of America · 2015Review
- Nanotechnology for enrichment and detection of circulating tumor cells.Nanomedicine (London, England) · 2015Review
- Enhancing reactivity for bioorthogonal pretargeting by unmasking antibody-conjugated trans-cyclooctenes.Bioconjugate chemistry · 2015Article
- Nanoparticle Detection of Urinary Markers for Point-of-Care Diagnosis of Kidney Injury.PloS one · 2015Article
- Ferroferric oxide nanoparticles induce prosurvival autophagy in human blood cells by modulating the Beclin 1/Bcl-2/VPS34 complex.International journal of nanomedicine · 2015Article
- Magnetic sensing technology for molecular analyses.Lab on a chip · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
Abstract
Advances in nanotechnology and microfluidics are enabling the analysis of small amounts of human cells. We tested whether recently developed micro-nuclear magnetic resonance (μNMR) technology could be leveraged for diagnosing pulmonary malignancy using fine needle aspirate (FNA) of primary lesions and/or peripheral blood samples. We enrolled a cohort of 35 patients referred for CT biopsy of primary pulmonary nodules, liver or adrenal masses and concurrently obtained FNA and peripheral blood samples. FNA sampling yielded sufficient material for μNMR analysis in 91% of cases and had a sensitivity and specificity of 91.6% and 100% respectively. Interestingly, among blood samples with positive circulating tumor cells (CTC), μNMR analysis of each patient's peripheral blood led to similar diagnosis (malignant vs benign) and differential diagnosis (lung malignancy subtype) in 100% and 90% (18/20) of samples, respectively. μNMR appears to be a valuable, non-invasive adjunct in the diagnosis of lung cancer. FROM THE CLINICAL EDITOR: The authors of this study established that recently developed micro-nuclear magnetic resonance (μNMR) technology can be leveraged for diagnosing pulmonary malignancy using fine needle aspirate (FNA) of primary lesions and/or peripheral blood samples derived from 35 patients, suggesting practical clinical applicability of this technique.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.